Overview Dividends

(ALKS) Alkermes - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE00B56GVS15

Schizophrenia, Bipolar, Alcohol, Opioid, Injectable

Biotechnology
Market Cap in USD: 4,848m

IPO / Inception: 1991-07-16
Return 12m vs S&P 500: -12.0%

EPS (Earnings per Share)

EPS CAGR: -33.78%
EPS Trend: 45.3%

Last SUE: -1.93
Qual. Beats: 0

Revenue

Rev. CAGR: 5.33%
Rev. Trend: 48.2%

Last SUE: 1.66
Qual. Beats: 2

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	34.7%
Value at Risk 5%th	52.6%
Relative Tail Risk	-7.88%

Reward TTM
Sharpe Ratio	0.16
Alpha	-7.99
CAGR/Max DD	0.08

Character TTM
Hurst Exponent	0.471
Beta	0.598
Beta Downside	0.753

Drawdowns 3y
Max DD	31.58%
Mean DD	15.53%
Median DD	16.30%

Description: ALKS Alkermes November 07, 2025

Alkermes plc (NASDAQ: ALKS) is an Ireland-based biopharma that develops, markets, and licenses drugs for unmet needs in neurology and psychiatry, primarily in the United States. Its commercial portfolio includes ARISTADA (long-acting injectable for schizophrenia), ARISTADA INITIO, VIVITROL (alcohol-use disorder and opioid-dependence prevention), and the oral antipsychotic LYBALVI, while its pipeline targets additional neurological disorders.

Key recent metrics: FY 2023 revenue was $1.22 billion, driven 68 % by ARISTADA sales; cash and cash equivalents stood at $514 million at year-end, providing runway for pipeline advancement; and the company reported a net loss of $84 million, reflecting ongoing R&D spend and amortization of acquisition intangibles.

Strategic partners include multiple Janssen entities, which supply both co-development funding and global commercialization reach. Alkermes also monetizes its proprietary drug-delivery platforms through licensing agreements, adding a non-dilutive revenue stream.

Sector-level drivers that shape Alkermes’ outlook are the expanding U.S. mental-health spending (projected CAGR ≈ 5 % through 2028) and the regulatory environment that increasingly favors long-acting injectables for adherence-critical conditions, both of which can amplify ARISTADA’s market share.

For a deeper dive into Alkermes valuation metrics and comparable peers, the ValueRay platform offers a concise, data-driven overview.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (338.8m TTM) > 0 and > 6% of Revenue (6% = 91.3m TTM)

FCFTA 0.21 (>2.0%) and ΔFCFTA 6.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 83.30% (prev 73.78%; Δ 9.52pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.23 (>3.0%) and CFO 541.1m > Net Income 338.8m (YES >=105%, WARN >=100%)

Net Debt (-544.9m) to EBITDA (435.8m) ratio: -1.25 <= 3.0 (WARN <= 3.5)

Current Ratio 3.67 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (168.5m) change vs 12m ago 0.89% (target <= -2.0% for YES)

Gross Margin 86.04% (prev 83.17%; Δ 2.87pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 67.84% (prev 69.83%; Δ -1.99pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 87.27 (EBITDA TTM 435.8m / Interest Expense TTM 4.65m) >= 6 (WARN >= 3)

Altman Z'' 2.31

(A) 0.54 = (Total Current Assets 1.74b - Total Current Liabilities 474.4m) / Total Assets 2.33b

(B) -0.34 = Retained Earnings (Balance) -784.1m / Total Assets 2.33b

(D) -1.31 = Book Value of Equity -783.4m / Total Liabilities 596.1m

Total Rating: 2.31 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 89.16

1. Piotroski 6.50pt

2. FCF Yield 12.89%

3. FCF Margin 32.27%

4. Debt/Equity 0.04

5. Debt/Ebitda -1.25

6. ROIC - WACC (= 12.86)%

7. RoE 21.40%

8. Rev. Trend 48.19%

9. EPS Trend 45.35%

What is the price of ALKS shares?

As of January 09, 2026, the stock is trading at USD 29.60 with a total of 2,311,441 shares traded.
Over the past week, the price has changed by +4.74%, over one month by +0.65%, over three months by -6.06% and over the past year by +4.15%.

Is ALKS a buy, sell or hold?

Alkermes has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy ALKS.

Strong Buy: 8
Buy: 1
Hold: 6
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the ALKS price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	43.8	48%
Analysts Target Price	43.8	48%
ValueRay Target Price	28.3	-4.6%

ALKS Fundamental Data Overview January 09, 2026

Market Cap USD = 4.85b (4.85b USD * 1.0 USD.USD)
P/E Trailing = 14.322
P/E Forward = 18.315
P/S = 3.1866
P/B = 2.7414
P/EG = -1057.29
Beta = 0.429
Revenue TTM = 1.52b USD
EBIT TTM = 405.6m USD
EBITDA TTM = 435.8m USD
Long Term Debt = 71.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.63m USD (from shortTermDebt, last quarter)
Debt = 71.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -544.9m USD (from netDebt column, last quarter)
Enterprise Value = 3.81b USD (4.85b + Debt 71.6m - CCE 1.11b)
Interest Coverage Ratio = 87.27 (Ebit TTM 405.6m / Interest Expense TTM 4.65m)
FCF Yield = 12.89% (FCF TTM 490.9m / Enterprise Value 3.81b)
FCF Margin = 32.27% (FCF TTM 490.9m / Revenue TTM 1.52b)
Net Margin = 22.27% (Net Income TTM 338.8m / Revenue TTM 1.52b)
Gross Margin = 86.04% ((Revenue TTM 1.52b - Cost of Revenue TTM 212.4m) / Revenue TTM)
Gross Margin QoQ = 86.91% (prev 87.34%)
Tobins Q-Ratio = 1.63 (Enterprise Value 3.81b / Total Assets 2.33b)
Interest Expense / Debt = 6.49% (Interest Expense 4.65m / Debt 71.6m)
Taxrate = 17.85% (18.0m / 100.7m)
NOPAT = 333.2m (EBIT 405.6m * (1 - 17.85%))
Current Ratio = 3.67 (Total Current Assets 1.74b / Total Current Liabilities 474.4m)
Debt / Equity = 0.04 (Debt 71.6m / totalStockholderEquity, last quarter 1.73b)
Debt / EBITDA = -1.25 (Net Debt -544.9m / EBITDA 435.8m)
Debt / FCF = -1.11 (Net Debt -544.9m / FCF TTM 490.9m)
Total Stockholder Equity = 1.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.54% (Net Income 338.8m / Total Assets 2.33b)
RoE = 21.40% (Net Income TTM 338.8m / Total Stockholder Equity 1.58b)
RoCE = 24.50% (EBIT 405.6m / Capital Employed (Equity 1.58b + L.T.Debt 71.6m))
RoIC = 21.04% (NOPAT 333.2m / Invested Capital 1.58b)
WACC = 8.18% (E(4.85b)/V(4.92b) * Re(8.22%) + D(71.6m)/V(4.92b) * Rd(6.49%) * (1-Tc(0.18)))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.48%
[DCF Debug] Terminal Value 80.68% ; FCFE base≈420.6m ; Y1≈511.5m ; Y5≈844.5m
Fair Price DCF = 84.27 (DCF Value 13.91b / Shares Outstanding 165.1m; 5y FCF grow 23.10% → 3.0% )
EPS Correlation: 45.35 | EPS CAGR: -33.78% | SUE: -1.93 | # QB: 0
Revenue Correlation: 48.19 | Revenue CAGR: 5.33% | SUE: 1.66 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.38 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=1
EPS next Year (2026-12-31): EPS=2.16 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+12.2% | Growth Revenue=+22.8%

Additional Sources for ALKS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle